Trial results for a combination study (NCT05054725) investigating RMC-4630 and Sotorasib for non-small cell lung cancer (NSCLC) subjects with a KRASG12C mutation were posted on ClinicalTrials.gov on 2026-01-06. This update provides new data for clinicians and researchers exploring therapeutic options for patients who have failed prior standard therapies.
Background
The study, identified as NCT05054725, is a combination study designed to evaluate RMC-4630 and Sotorasib in NSCLC subjects with a KRASG12C mutation. Participants in this study had previously failed prior standard therapies for their condition.
What this means
The posting of these trial results offers new insights into the potential role of combining RMC-4630 with Sotorasib for NSCLC patients with a KRASG12C mutation who have progressed after prior treatments. Clinicians and researchers can now access and review these findings, which may inform future treatment strategies for this specific patient population.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a comprehensive registry and results database for clinical studies. The record for study NCT05054725, titled "Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies," was posted on 2026-01-06.